Document is current
Any future updates will be listed below
-
Authors
-
Funding
Funding for this research was provided by:
Novartis Pharma KK
- License Information
-
More Information
Article History
Received: 7 October 2019
Revised: 22 April 2020
Accepted: 25 April 2020
First Online: 11 May 2020
Compliance with ethical standards
:
: Dr. Norio Komatsu has received personal fees from AbbVie GK, Otsuka Pharmaceutical Co., Ltd., Celgene KK, Japan Tobacco Inc, Novartis Pharma KK, and PharmaEssentia Japan KK; and grants from Otsuka Pharmaceutical Co., Ltd., Shire Japan KK, Novartis Pharma KK, PharmaEssentia Japan KK, Fuso Pharmaceutical Industries, Ltd., Fujifilm Wako Pure Chemical Corporation; Chugai Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Takeda Pharmaceutical Co., Ltd., Pfizer Japan Inc, Sumitomo Dainippon Pharma Co., Ltd., and Bristol-Myers Squibb KK. GyungJin Jun and Toshio Yonezu are employees of Novartis Pharma KK. Dr. Yasuo Ohashi has received personal fees from Daiichi Sankyo Co., Ltd., Chugai Pharmaceutical Co., Ltd., and Sanofi KK; and has received grants from Medical Member System KK.
: The authors confirm that the data supporting the findings of this study are available within the article and/or its supplementary materials. Novartis is committed to sharing with qualified external researchers access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided are anonymized to respect the privacy of patients who have participated in the trial, in line with applicable laws and regulations. This trial data availability is according to the criteria and the process described on .
